Steven

Finance, Economics, International Business. Biotech Investor. Business partner.

[SemperFITrader @SouthernDrive21]

$NWBO Here is the two CHM Minutes where Licensing and Brain Cancer mentioned. Whether this the first and second RFI is my main focus point. If the second RFI was indeed 11/28/2026 NWBO had 3 months to respond at this time of clock stop, then MHRA has up 210 days to make the final decision on approval. (Total of 300 days, 3 months + 210) If necessary a third RFI would be sent to resolve any final minor outstanding issues and switch off the clock again up to 3 months plus 210 days or 300 days max for approval decision.
If we did get an RFI Nov 28th of 2025, max decision with no 3rd RFI would be 09/24/2026. 90 days ended FEB 25th, 2026. So MHRA is in decision mode of either 3rd RFI or a final decision by end of September at the latest is my estimation assuming second RFI November 28th, 2025.
I have question in now about time frame in general to MHRA, I am not mentioning DCVAX by name, I want to know how an application can go 869 days without a decision based on their on guidance here. https://t.co/LIT0fysUCY

[Matthew Hassan @HassanClan]

#DCVax is a #paradigmshift in #cancer from $NWBO for all #solid tumor. It is #autologous meaning ...
#moral - no questionably sourced cells
#safe - no deadly side-effects
#effective - customized just for you
#REPEATABLE - do it again overcoming resistance from mutations

[Hoffmann @hoffmann6383]

@DaveH20122790 that's a big deal if the magistrate believes the Defendant Market Makers' trading algorithms are discoverable

$NWBO

See footnote 6 in the attached image

[Ida Bogac @albtur_mnymkrs]

$nwbo #dcvax

Tomorrow @ 9 AM

[Steven @Steven_DB89]

@SouthernDrive21 What’s your take @hoffmann6383

[Jamie @Jamie_yyds]

$NWBO
A single spark — the DCVax‑L approval — ignites the entire DCVax platform!

MHRA… we wait… still...

[PK_Fund @PK_Fund]

$NWBO

Site open.

https://t.co/uZBSw0YeVh

[Lou Smith 🍀 @smith348572]

#DCVAX-l $NWBO

Personalized dendritic cell vaccine + checkpoint inhibitor may become one of the most powerful combinations in oncology.

Look at these extraordinary recurrent GBM survival results using ATL-DC (a dendritic cell vaccine platform similar to DCVax-L) combined with PD-1 blockade such as Keytruda.

The data suggest that timing and sequencing of immunotherapy may dramatically impact survival outcomes.

In the chart:

Patients receiving ATL-DC + PD-1 inhibitor showed median overall survival “not reached”
The comparison arm showed median OS of only 275 days
The survival curves separate significantly over time
A substantial proportion of patients remained alive far beyond historical expectations for recurrent glioblastoma.

This is exactly why many believe personalized cancer vaccines could become the ideal backbone therapy for checkpoint inhibitors.

The future of oncology may not be chemo alone anymore.

It may be:
Personalized vaccine + checkpoint inhibitor + targeted immune modulation.

#NWBO #DCVax #Glioblastoma #GBM #CancerResearch #Immunotherapy #Keytruda #Biotech #Oncology #CancerVaccine

[Hoffmann @hoffmann6383]

🧑‍⚖️Two Rulings, Two (mostly) wins for $NWBO

The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.)

The Docket: https://t.co/2vLwDOXAki

Keep in mind these are discovery rulings. That being said, these were two important wins for $NWBO in their spoofing lawsuit against seven of the largest market makers in the world.

✅May 19, 2026 Ruling

The 'I don't care to read the below quotes summary':

This ruling stops the Defendants from getting a sneak peak at $NWBO's underlying analysis and protects Joshua Mitts from having to produce a burdensome document by document privilege log.

"...the Court hereby GRANTS the motion for a protective order to the extent indicated below."

"The Court is unpersuaded by Citadel’s argument that NWBO waived Rule 26(b)(4)(D) protections because statistical analyses prepared by Professor Mitts were incorporated into the Second Amended Complaint (“SAC”)."

"The Court also finds that a detailed privilege log is unwarranted to the extent the documents sought are protected by Rule 26(b)(4)(D)."

"Although the Court thus finds that Rule 26(b)(4)(D) shields Mitts from providing documents concerning his work as a non-testifying consulting expert, it is not clear that this relieves him of any obligation to comply with the subpoena."

"Citadel, however, states that it would be willing to accept a categorical privilege log, and the Court agrees that a categorical log, with information as to date range, general subject matter, and the privilege(s) asserted, would be appropriate."

✅May 20, 2026 Ruling

The tldr summary:

The Court is granting $NWBO's request for a discovery continuance but they're annoyed at the slow pace of discovery so the Court is taking steps to speed things up.

"Having reviewed this letter, Defendants’ response (Dkt. No. 274), and the parties’ May 4, 2026 status report (Dkt. No. 270), the Court is not satisfied with the progress of discovery in this case. The original Scheduling Order, entered following the Initial Case Management Conference held on June 5, 2025, set a deadline for substantial completion of document production of August 29, 2025. (Dkt. No. 218 at 3). This date was mutually agreed to, and indeed proposed by, the parties. (Dkt. No. 205 at 7). Yet eleven months after the ICMC, and with the extended deadline for substantial completion of document discovery just two weeks away (Dkt. No. 254), Plaintiff writes that “the parties have yet to agree on search terms for either NWBO or Defendants.” (Dkt. No. 269 at 1 n.2; emphasis added). The Court does not understand how that could possibly be the case if the parties were working diligently, cooperatively, and in good faith to complete discovery in the allotted time. Nor does the Court understand how, after eleven months of discovery, so few documents have been produced in a case of this nature. To the extent there is any bona fide issue relating to search terms (the Court recognizes that Defendants say they understood that the search terms, at least for their own production, were already agreed to and that they produced documents based on that understanding, see Dkt. No. 274 at 2)), it must be resolved immediately. Similarly, any dispute as to Defendants’ production of trading data, described in the parties’ exchange of letters in November 2025 (see Dkt. No. 274 Exs. B and C), must be resolved immediately. The parties shall meet and confer and, by no later than next Friday, May 29, 2026, file a joint status letter that either (a) reports that these issues have been resolved (for both NWBO’s and Defendants’ productions) and provides a revised deadline for substantial completion of document production no later than July 31, 2026; or (b) states that the Court’s intervention is needed and provides each party’s position in no more than 3 pages for each side. To facilitate discussions regarding search terms, Plaintiff shall provide Defendants with string-by-string hit counts (and not just an aggregate hit count), or forfeit any ability to argue that Defendants’ proposed search terms are unduly burdensome. Pending receipt of the parties’ May 29 letter, the Court holds in abeyance NWBO’s request for an extension of discovery deadlines. SO ORDERED."

[SemperFITrader @SouthernDrive21]

$NWBO Judge has now signed

[Sun & Sea 🌈 @MarisolCA20]

OK now I'm buying $50 million worth of $NWBO. Cancer therapy for dogs as well‼️
https://t.co/IPXxzTu5ih

[Mark Thompson @METhompson72]

$NWBO - Northwest Biotherapeutics
I spent 6 months due diligence on this pick, then went large.
I have met with all the management and visited the Sawston manufacturing plant twice.
I had oncologists and neurologists review their clinical data.
I am betting that the tech is real, it’s is transformative, it is applicable to all solid tumours and cancers.
I am betting that it will receive regulatory approval.
I am betting that the shorts are screwed.

[Michael Boyd @MichaelBoy64231]

$NWBO Moderna terminated their skin cancer trial combo with Kaytuda. DcVaxL is King!

https://t.co/avmqfpmhwN

[Mark Thompson @METhompson72]

@Bigsky716 Timing is everything - the risk / reward asymmetry on this looks outrageous!

[Mark Thompson @METhompson72]

I have 2 new big positions and can reveal one today.
I have recycled $TUN and $EQR profits into...
Northwest Biotherapeutics. $NWBO
This news of the appointment of the incredible Dr Annalisa Jenkins to the advisory board should not be underestimated. Great people only involve themselves with great things.
https://t.co/pee5Wb9PWf

[Steven @Steven_DB89]

@SouthernDrive21 @Kenneth83risom @hoffmann6383 what’s your take on this?

[kristen shaughnessy @kshaughnessy2]

$NWBO

The six market maker defendants named in $NWBO spoofing lawsuit don’t want to hand over the trading data

They are trying all sorts of delay tactics.

“…Meanwhile, even though NWBO has produced 3,466 documents, no Defendant has produced more than 350 documents.

Despite this, Defendants have harassed NWBO with frivolous discovery requests requiring unnecessary burden and expense to contest….”

Courtesy:
@hoffmann6383

[SemperFITrader @SouthernDrive21]

@hoffmann6383 Thoughts on this, seems Judge asking for settlenment terms and not approving until he gets it.

[SemperFITrader @SouthernDrive21]

$NWBO See updates to the MHRA Mintues today.

I was looking for any new specific information related to DCVAX (3rd CHM meeting)

Here is what I see related to Brain Cancer:

But this is for ABRIDGED (Applications for new licences for known drug substances which rely in part on
previously submitted data or on data submitted by other licence holders)
https://t.co/9wVEH8Apan

[Andrew Caravello, DO @andrewcaravello]

$NWBO #DCVax #GBM

https://t.co/n434qzrcKL